Prostaglandins Leukot Essent Fatty Acids. 2020 Oct 1;162:102186. doi: 10.1016/j.plefa.2020.102186.

Randomized, double-blind, parallel, placebo-controlled trial.

96 CF patients (age >2 months) 44 female, age 14.6±11.9 years (48 DHA and 48 placebo) were included.

Patients were randomized to receive a seaweed DHA oil solution (50 mg/Kg/day) or matching placebo for 48 weeks.

terleukin [IL]-8), systemic (IL-8) and intestinal (calprotectin) inflammatory biomarkers. Secondary outcomes included other pulmonary (IL-1β, IL-6, neutrophil elastase, lactate and calprotectin) and systemic (serum-IL-1β, IL-6) inflammatory biomarkers, as well as clinical outcomes (FEV(1), pulmonary exacerbations, antibiotic use, nutritional status and quality of life).

At trial completion, there were no differences in all primary outcomes [serum-IL-8 (p=0.909), respiratory-IL-8 (p=0.384) or fecal calprotectin (p=0.948)], all secondary inflammatory biomarkers, or in any of the clinical outcomes evaluated. There were few adverse events, with similar incidence in both study groups.

In this study, long-term DHA supplementation in CF patients was safe, but did not offer any benefit on inflammatory biomarkers, or in clinical outcomes compared with placebo. (NCT01783613).

Omega-3 fatty acids, zinc and probiotics supplements in cystic fibrosis